BCR and leukemia: This patent provided the combination method in the prevention of the recurrence of leukemia, characterized by expression of BCR-ABL fusion protein that comprise: tyrosine kinase inhibitor inhibiting phosphorylation of BCR-ABL treating cancer and a peroxisome proliferator-activated receptor gamma agonist inhibiting signal transduction/transcription activator 5 (STAT5).